A Pilot Study to Enhance F18 FDG-PET Imaging of Prostate Cancers With the Metabolic Inhibitor Ranolazine

NCT01992016 NA COMPLETED Results posted

This pilot clinical trial studies fludeoxyglucose F18 (FDG)-positron emission tomography (PET) in imaging patients with prostate cancer treated with ranolazine. Diagnostic procedures, such as FDG-PET, may help find prostate cancer and find out how far the disease has spread. Giving ranolazine may enhance FDG-PET imaging by increasing the amount of glucose available for uptake by the scan.

Details

Lead sponsor	University of Colorado, Denver
Phase	NA
Status	COMPLETED
Enrolment	11
Start date	Mon Apr 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Wed Apr 11 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Adenocarcinoma of the Prostate
• Bone Metastases
• Soft Tissue Metastases
• Stage IIA Prostate Cancer
• Stage IIB Prostate Cancer
• Stage III Prostate Cancer
• Stage IV Prostate Cancer

Interventions

• Ranolazine

Countries

United States